Effects of smoked cannabis and oral ∆9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials

Journal of Cannabis Therapeutics

Volumn 1, Issue 1, 2001, Pages 29-42

  Musty, Richard E ^a   Rossi, Rita ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Cancer; Cannabinoid; Cannabis; Chemotherapy; Marijuana; Nausea; Tetrahydrocannabinol; Vomiting

Indexed keywords

EID: 84904549737     PISSN: 15299775     EISSN: None     Source Type: Journal    
DOI: 10.1300/J175v01n01_03     Document Type: Review

References (27)

1. Beck, T H, Ciociola, A A, Jones, S E, the Ondansetron Study Group. 1993. Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. Ann Intern Med, 118:407–13.
2. Behavioral Health Sciences Division. 1984. The Lynn Pierson Therapeutic Research Program, New Mexico:Health and Environment Department.
3. Behavioral Health Sciences Division. 1983. The Lynn Pierson Therapeutic Research Program, New Mexico:Health and Environment Department.
4. Board of Pharmacy, State of Tennessee. 1983. Annual Report:Evaluation of marijuana and tetrahydrocannabinol in the treatment of nausea and/or vomiting associated with cancer therapy unresponsive to conventional anti-emetic therapy:Efficacy and toxicity
5. Buser, K S, Joss, R A, Piquet, D. 1993. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorou-racil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. Ann Oncol, 4:475–9.
6. Chang, A E, Shiling, D J, Stillman, R C. 1979. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med, 91:819–24.
7. Crucitt, M A, Hyman, W, Grote, T. 1996. Efficacy and tolerability of oral ondan-setron versus prochlorperazine in the prevention of emesis associated with cyclo-phosphamide-based chemotherapy and maintenance of health-related quality of life. Clin Ther, 18(4):778–88.
8. Cupissol, D R, Serrou, B, and Caubel, M. 1990. The efficacy of granisetron as a prophylactic anti-emetic and intervention agent in high-dose cisplatin-induced emesis. Eur J Cancer, 26(1):23–7.
9. Department of Social Oncology, Evaluation Unit. 1982. State of Michigan, Marihuana Therapeutic Research Project.
10. Doblin, R, and Kleiman, M. 1991. Marijuana as antiemetic medicine:A survey of oncologists’ experiences and attitudes. J Clin Oncol, 9(5):1314–19.
11. Herrstedt, J, Sigsgaard, T, Boesgaard, M, Jensen, T, and Dombernowski, P. 1993. Ondansetron plus metopimazine compared with ondansetron in patients receiving moderately emetogenic chemotherapy. N Engl J Med, 328(15):1076–80.
12. Italian Group for Antiemetic Research. 1995. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. New Engl J Med, 332(1):1–5.
13. Jones, A L, Hill, A S, Soukop, M. 1991. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet, 338:483–87.
14. Joy, J, Watson, S J, and Benson, J A. 1999. Marijuana as medicine:Assessing the science base, Washington, DC:National Academy Press.
15. Kaasa, S, Kvaløy, S, Dicato, M A, the International Emesis Study Group. 1990. A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting:A randomized, double-blind study. Eur J Cancer, 26(3):311–14.
16. Kutner, M H. 1983. Evaluation of the use of both marijuana and THC in cancer patients for the relief of nausea and vomiting associated with cancer chemotherapy after failure of conventional anti-emetic therapy:Efficacy and toxicity, as prepared for the Composite State Board of Medical Examiners, Georgia Department of Health, by physicians and researchers at Emory University, Atlanta
17. Markman, M, Kennedy, A, Webster, K. 1996. Control of carbonplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone. Gyne-col Onco, 60:435–7.
18. 3(serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med, 322(12):816–21.
19. Michigan Cancer Foundation, Department of Social Oncology, Evaluation Unit. 1992. Michigan Department of Public Health Marijuana Therapeutic Research Project, Trial A 1980–81
20. Olver, I, Paska, W, Depierre, A. 1996. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ann Oncol, 7:945–52.
21. Perez, E A, Navari, R M, Kaplan, H G. 1997. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer, 5:31–7.
22. Randall, R C. 1990. Cancer Treatment & Marijuana Therapy, 225–34. Washington, DC:Galen Press. 1990
23. Research Advisory Panel. 1989. Cannabis Therapeutic Research Program Report to the California Legislature
24. Ritter, H L, Jr., Gralla, R J, Hall, S W. 1998. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. Cancer Invest, 16(2):87–93.
25. Roila, F, Tonato, M, Cognettti, F. 1991. Prevention of cisplatin-induced emesis:A double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol, 9(4):675–8.
26. Sekine, I, Nishiwaki, Y, Kakinuma, R. 1996. A randomized cross-over trial of granisetron and dexamethasone versus granisetron alone:The role of dexametha-sone on day 1 in the control of cisplatin-induced delayed emesis. Jp J Clin Oncol, 26(3):164–68.
27. Vinciguerra, V, Moore, T, and Brennan, E. 1988. Inhalation marijuana as an antiemetic for cancer chemotherapy. NY State J Med, 88:525–7.